By Bhanvi Satija

NEW YORK, June 3 (Reuters) - Telehealth platform Hims &

Hers said on Tuesday it will acquire London-based

startup Zava for an undisclosed amount, allowing it to launch

its offerings in Germany, France and Ireland and reach more

international patients.

The move comes as Hims is adjusting to a regulatory ban in

the United States on manufacturing mass copies of Novo Nordisk's

popular weight-loss drug Wegovy, that took effect on

May 22. Hims began offering copies of Wegovy in 2024, and saw a

boost in its revenues, when the branded version of the highly

in-demand drug was in shortage.

Shares of the telehealth firm have dropped nearly 9% in the

last two weeks. It recently entered into an agreement with Novo

to help patients access brand-name Wegovy, and plans to enter

the market for low testosterone and menopause treatments in

pursuit of new growth opportunities.

Hims did not provide financial terms of the deal, but a

company spokesperson said these details will be shared with its

second-quarter results expected in August.

It plans to fund the acquisition through cash on its balance

sheet at closing. The deal is expected to close in the second

half of this year.

Backed by equity firm HPE Growth, Zava provides medical

consultations and delivery of prescription medicines - including

weight loss drugs Mounjaro and Wegovy - to its more than 1

million customers across United Kingdom, Germany, France and

Ireland.

Hims said it plans to introduce personalized skin care,

weight loss and other offerings for patients in these markets

and will introduce an option for patients to interact with their

healthcare providers in local languages.

Last week, Hims also said it will cut about 4% of its

workforce but still plans to hire for roles related to its

long-term growth strategy.

(Reporting by Bhanvi Satija in New York; Editing by Lincoln

Feast.)